Table 2.
Cytotoxic activity of different alkali-solubilized and trypsinized parasporal crystal proteins against cancerous cell lines 24-h post-treatment.
| Bt isolate/Compound | HeLa | HT-29 | ||
|---|---|---|---|---|
| Inhibition (%) * | IC50 # (µg/mL) | Inhibition * (%) | IC50 (µg/mL) | |
| Bt1 | 38 | 3.2 | 3 | nd a |
| Bt2 | 40 | 5.7 | 2 | nd |
| Bt3 | 35 | 5.4 | 0 | nd |
| Bt4 | 38 | 5.4 | 2 | nd |
| Bt5 | 40 | 9.5 | 3 | nd |
| Bt6 | 42 | 14.2 | 0 | nd |
| Bt7 | 47 | 5.6 | 0 | nd |
| Bt8 | 40 | 6.4 | 0 | nd |
| Bt9 | 43 | 6.1 | 4 | nd |
| Dasatinib | 58 | 24.4 | nd | nd |
Inhibition (%) *, Percentage of inhibition of cell proliferation at PS concentration of 12.5 µg/mL, relative to Na2CO3 buffer control at equivalent serially-diluted concentration; # IC50 values were calculated from the data of the cytotoxicity dose–response curve against HeLa cell line. nd a, not determined. Dasatinib, is a positive control anticancer drug that acts as a potent multi-targeted kinase inhibitor of BCR-ABL and SRC family kinases.